{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:30Z","timestamp":1787010150370,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703062"],"award-info":[{"award-number":["81703062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system (CNS), concerned because of its high pathogenicity, high risk of recurrence, and poor prognosis. Optic neuritis (ON) is the first manifestation in 30% to 50% of NMOSD patients, and eventually involved optic nerve in 70% of patients. The idiopathic ON associated with NMO is called NMO-associated ON(NMO-ON). There are substantial costs to the countries and individuals associated with treatment of NMO-ON. Intravenous corticosteroids (IVCSs), as the first-line therapy, leads to unsatisfactory outcomes for NMO-ON and is associated with potential adverse events (AEs). Emerging evidences have proved the important value and potential prospect of plasma exchange (PLEX) in NMO-ON. Although PLEX is increasingly used in NMO-ON, its therapeutic effect and safety are still controversial. There are no systematic reviews yet that evaluated the effects of PLEX against other therapies in patients with NMO-NO. It is therefore timely to perform a systematic review to assess the efficacy and safety of PLEX on current research for its potential use in clinical practice in treating NMO-ON.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The systematic review will include all of the randomized controlled trials (RCT) on the efficacy and safety of PLEX for NMO-ON. A relevant literature search by sensitive search strategies was conducted using the following electronic databases from their inception to November 30, 2019: PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and CBM. We will also search registers of clinical trials, potential gray literature, and conference abstracts. There are no limits on language and publication status. The literature screening, data extraction, and quality assessment will be conducted by 2 reviewers independently. The reporting quality and risk of bias will be assessed by other 2 researchers. Best-corrected visual acuity (BCVA), annualized relapse rate (ARR), the frequency and extent of adverse events (AEs) will be evaluated as the primary outcome. The secondary outcomes will include expanded disability status scales (EDSS), relapse-free rate, peri-papillary retinal nerve fibers layer (pRNFL) or macular volume, visual electrophysiology examinations, standard automated perimetry examinations, time to the next attack. Meta-analysis will be performed using RevMan5.3 software provided by the Cochrane Collaboration and Stata 12.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This study will provide a comprehensive review based on current evidence of PLEX treatment for NMO-ON in several aspects, including BCVA, ARR, the frequency and extent of adverse events (AEs), EDSS, relapse-free rate, etc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The conclusion of this study will provide evidence to determine whether PLEX is an effective and safe intervention for patients with NMO-ON.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination:<\/jats:title>\n                    <jats:p>It is not necessary to obtain ethical approval for this study, given that this protocol is for a systematic review. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number:<\/jats:title>\n                    <jats:p>PROSPERO CRD 42020162585.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000021067","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T05:04:54Z","timestamp":1594271094000},"page":"e21067","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-268X","authenticated-orcid":false,"given":"Mengyu","family":"Han","sequence":"first","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine"},{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Nong","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine"},{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine"},{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Hao","sequence":"additional","affiliation":[{"name":"Science and education Department, Shenzhen Baoan Shiyan People's Hospital, Shenzhen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The Immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-012-6594-3","article-title":"On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica","volume":"260","author":"Jarius","year":"2013","journal-title":"J Neurol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.06.002","article-title":"The role of AQP4 in neuromyelitis optica: more answers, more questions","volume":"298","author":"Yang","year":"2016","journal-title":"Neuroimmunol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"e79649","DOI":"10.1371\/journal.pone.0079649","article-title":"Neuromyelitis optica in Austria in 2011: to bridge the gap between neuro-epidemiological research and practice in a study population of 8.4 million people","volume":"8","author":"Aboul-Enein","year":"2013","journal-title":"PLoS One"},{"key":"R7-20230915","first-page":"204","article-title":"A descriptive study of prevalence. clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran","volume":"14","author":"Kashipazha","year":"2015","journal-title":"Iran J Neurol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Hideki","year":"2017","journal-title":"Neurology"},{"key":"R9-20230915","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","author":"Maria","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.autrev.2014.01.034","article-title":"Diagnosis and classification of neuromyelitis optica (Devic's syndrome)","volume":"13","author":"Drori","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial","volume":"115","year":"2008","journal-title":"Ophthalmology"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"7180632","DOI":"10.1155\/2017\/7180632","article-title":"Mitochondrial uncoupler prodrug of 2,4-dinitrophenol, mp201, prevents neuronal damage and preserves vision in experimental optic neuritis","volume":"2017","author":"Khan","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1352458512471875","article-title":"Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders","volume":"19","author":"Lim","year":"2013","journal-title":"Mult Scler"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0404.2011.01612.x","article-title":"Treatment of steroid-unresponsive optic neuritis with plasma exchange","volume":"126","author":"Roesner","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","article-title":"Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders","volume":"20","author":"Sfisupa-Olan","year":"2018","journal-title":"Muh Scler Relat Disord"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders","volume":"22","author":"Kumawat","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10384-018-0602-9","article-title":"Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders","volume":"62","author":"Sotaro","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.msard.2019.101506","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation [published correction appears in BMJ","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21680","article-title":"A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults","volume":"21","author":"Squires","year":"2017","journal-title":"Health Technol Assess"},{"key":"R30-20230915","first-page":"262350","article-title":"Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials","volume":"2014","author":"Lavery","year":"2014","journal-title":"Mult Scler Int"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jca.20217","article-title":"Predictors of complications in therapeutical plasma exchange","volume":"24","author":"Bramlage","year":"2009","journal-title":"J Clin Apher"},{"key":"R32-20230915","first-page":"1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurol Int"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2046-4053-3-37","article-title":"Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation","volume":"3","author":"Savovi\u0107","year":"2014","journal-title":"Syst Rev"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-017-0630-4","article-title":"Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes","volume":"6","author":"Chen","year":"2017","journal-title":"Syst Rev"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12950-017-0174-3","article-title":"Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome","volume":"14","author":"Shih","year":"2017","journal-title":"J Inflamm (LOND)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:37:13Z","timestamp":1694813833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021067"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":35,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021067","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}